Background
==========

Many phenotypes may be influenced by the prenatal environment of the mother and/or maternal care, and these maternal effects may have a heritable component. Much research has focused on the impact of measurable properties of the mother (e.g., adiposity, diabetes, alcohol, or tobacco use) on subsequent phenotypes in their children (e.g., birthweight \[[@B1]\], insulin resistance \[[@B2]\], cognitive function \[[@B3]\]). A more general question is: does the mother\'s measured **genotype**influence offspring phenotypes, whether or not the intermediate maternal phenotypes are known or measurable? This \'agnostic\' (with respect to maternal phenotype) approach has the potential both to identify novel genetic variants of maternal effect and, via \'reverse epidemiology,\' to identify novel maternal phenotypes for such effects.

For the purposes of this study, we accept the strict definition of a genetic maternal effect as the indirect effect of maternal genotype on offspring phenotype \[[@B4]\], as distinct from asymmetric transmission of parental alleles (e.g., mitochondrial inheritance \[[@B5]\]) or asymmetric expression of alleles in the offspring depending on parent of origin (e.g., imprinting \[[@B6]\]). Here we develop mixed variance-components models in the computer program SOLAR \[[@B7]\] to estimate maternal random effects on quantitative phenotypes, and use the best such models as null hypotheses for measured-genotype genome-wide association tests of single-nucleotide polymorphism (SNP) genotypes of individuals and their mothers.

Methods
=======

Data
----

Data include adult quantitative phenotypes and Affymetrix SNP genotypes provided in the Genetic Analysis Workshop (GAW) 16 Framingham Heart Study (FHS) data release (Problem 2). All authors of this study are \'approved users\' of these data per the NHLBI Data Use Certification of April 2008. Analysis of these data was approved by the Institutional Review Board of the University of Texas Health Science Center, San Antonio.

Outlying phenotype measurements (more than four standard deviations from the mean) were removed from the lipid measures (10 for total cholesterol, 9 for high-density lipoprotein (HDL), 43 for triglyceride (TG)) on the assumption that these represented assay errors. The data were normal-quantile-transformed before analysis using the SOLAR \"inormal\" option to meet the distributional assumptions of the variance components and regression methods. The normal quantile (\"inverse normal\") transformation is robust to a range of departures from normality and also removed scale effects by standardizing the data. Transformations of this type are convenient for batch processing of multiple phenotypes (e.g., Peng et al. \[[@B8]\]).

Individuals with incomplete genotype data were given imputed genotype scores for the missing markers using the \-- infer option in the computer program Merlin \[[@B9],[@B10]\] Merlin imputes an expected genotype score based on the probability of each possible genotype at a locus given information on marker allele frequency, adjacent markers, and pedigree relationships. We chose not to exclude any SNPs or individuals on the basis of number of incomplete genotypes (unless no genotypes were available at all), given the robustness of imputation from family data \[[@B11]\]. Genotypes were similarly imputed for **all**SNPs for the non-genotyped implicit mothers of genotyped and phenotyped founders. These maternal genotypes entered the association analysis as properties of their offspring (see \"Measured genotype analysis,\" below); the \'virtual\' mothers did not enter the analysis otherwise.

Variance components estimation
------------------------------

We have implemented in SOLAR a general model for incorporating polygenic maternal effects \[[@B12]-[@B14]\]. Briefly, in the absence of dominance and epistatic effects, the phenotypic covariance between individuals *i*, *j*may be decomposed into additive genetic and environmental components in the usual way:

where *I*(*i*, *j*) is an identity term (1 if *i*= *j*, or 0 otherwise), *ϕ*(*i*, *j*) is a coefficient of coancestry, *σ*~*z*~(*i*, *j*) is the phenotypic covariance, and *σ*^2^~*e*~and *σ*^2^~*a*~are, respectively, environmental and additive genetic variances. The additive genetic covariance can be further decomposed to include maternal effects:

where 2*ϕ*(*i*, *mo_j*) is the coancestry coefficient for *i*and the mother of *j*, and 2*ϕ*(*mo*\_*i*, *mo_j*) is the coancestry of the mothers. is the additive genetic variance due to maternal effects, and *ρ*~*a*,\ *am*~is the additive genetic correlation between direct and maternal effects. Decomposition of the environmental component of Eq. 1 is modified from Eq. 14 of Bijma \[[@B14]\]:

with *R*= 1 if *i*= *j*(equivalent to the identity matrix in Eq. 1), *ρ*~*sib*~∈ \[0,1\] if *i*, *j*are siblings or half-siblings, ρ~mo~∈ \[-1,1\] if *i*, *j*are mother and offspring, or 0 otherwise. Our modification from Bijma \[[@B14]\] was that twins were not treated differently than other siblings because dizygotic twins could not be distinguished in the de-identified FHS data. Our full mixed model also included the fixed effects of relevant covariates and the random effect of mitochondrial inheritance, *σ*^2^~*mito*~; the mitochondrial variance component is structured by a matrix whose elements are 1 if *i*, *j*belong to the same matriline or 0 otherwise, as described by Czerwinski et al. \[[@B15]\].

Measured genotype analysis
--------------------------

Measured genotype analysis was conducted for each polymorphic SNP by including its genotype score (the number of copies of the minor allele, range \[0,2\] with non-integral values for imputed genotypes) as a covariate in the mixed model \[[@B16]\]. Unlike standard association analysis, we included the indirect effect of the mother\'s genotype in addition to the direct effect of the focal subject\'s genotype. These effects were tested separately, with an additional test of the mother\'s genotype conditional on that of the focal subject. The latter test was intended to account for the non-independence of maternal and offspring genotypes: reduction of evidence of maternal association in the conditional test would suggest that the unconditioned maternal effect represented a \'bleed-through\' of the direct effect, while an increase in evidence would suggest that the locus affects the trait both directly and indirectly.

Results
=======

Screening for evidence of maternal effects
------------------------------------------

We tested our maternal random effects model on quantitative phenotypes (height, weight, body mass index (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP), fasting total and HDL cholesterol and triglycerides) in individuals measured at exams when they were as similar as possible in mean age (Table [1](#T1){ref-type="table"}). Sex, age, age^2^, and their interactions were included as covariates in all models, and use of antihypertensive medication was a covariate for SBP and DBP. The use of an indicator variable-type covariate for medication has been questioned, especially with regard to BP \[[@B17],[@B18]\]. In response to a reviewer\'s concern, we re-ran the BP analyses while correcting for medication by adding 10 mm Hg to BP measures in medicated individuals, as recommended \[[@B17]\]; this did not substantially change our results (data not shown). The impact of alternative corrections for medication may have been greater if we had proceeded to association analysis of the BP traits, because we would then be testing for a difference in means. HDL-C and TG measures were not available for the original cohort and did not give evidence of maternal effect (data not shown); they were not considered further. Results for the remaining phenotypes are given in Table [2](#T2){ref-type="table"}.

###### 

FHS cohorts/examination periods used in this study

  FHS Cohort/Exam Period            *N*     Age in years \[mean (SE)\]
  --------------------------------- ------- ----------------------------
  Original/Exam 4 (1954-1958)       356     40.9 (0.20)
  Offspring/Exam 3 (1983-1987)      2,422   46.3 (0.19)
  Generation 3/Exam 1 (2002-2005)   3,997   40.2 (0.14)

###### 

Parameter estimates \[mean (SE)\] for saturated random-effects model

  Trait      σ^2^~a~       σ^2^~am~      ρ~a,\ am~      σ^2^~e~       ρ~sib~        ρ~mo~          σ^2^~mito~
  ---------- ------------- ------------- -------------- ------------- ------------- -------------- -------------
  Height     0.64 (0.02)   0.19 (0.07)   -0.21 (0.16)   0.23 (0.08)   0.03 (0.25)   0.05 (0.29)    0.05 (0.12)
  Weight     0.68 (0.03)   0.22 (0.08)   -0.38 (0.16)   0.50 (0.04)   0.00^a^       0.02 (0.12)    0.00 (0.09)
  BMI        0.76 (0.04)   0.24 (0.10)   -0.51 (0.14)   0.60 (0.04)   0.00^a^       -0.02 (0.12)   0.00^a^
  SBP        0.53 (0.04)   0.04 (0.04)   -1.00^a^       0.74 (0.04)   0.04 (0.03)   0.00 (0.05)    0.00^a^
  DBP        0.48 (0.04)   0.24 (0.09)   -0.33 (0.30)   0.80 (0.03)   0.00^a^       0.07 (0.05)    0.00 (0.08)
  Cholest.   0.58 (0.05)   0.12 (0.32)   -0.11 (0.75)   0.75 (0.06)   0.05 (0.06)   0.06 (0.07)    0.13 (0.09)

^a^Estimate on boundary; no SE computed.

Table [3](#T3){ref-type="table"} gives the log likelihoods for the minimal polygenic (PG) model (Eq. 1), a PG model with mitochondrial effect, and the saturated model of Table [2](#T2){ref-type="table"}. Height showed the strongest evidence of a maternal effect (compared with the PG-mito model, *P*= 0.02 at 4 degrees of freedom; 4 df is probably over-conservative \[[@B19]\]). Interestingly, this trait initially showed a significant mitochondrial effect compared with the PG model (*P*= 0.008, 1 df), evidently capturing some of the maternal effects when these were not explicitly modeled.

###### 

Comparative evidence (log likelihoods), variance-components models

  Model                       Height   Weight    BMI       SBP       DBP       Cholest.
  --------------------------- -------- --------- --------- --------- --------- ----------
  Polygenic                   -112.7   -1850.0   -2788.8   -2460.2   -2724.4   -2615.8
  Polygenic + mitochondrial   -109.1   -1850.0   -2788.8   -2460.2   -2724.4   -2613.9
  Saturated                   -103.3   -1846.9   -2783.5   -2458.4   -2722.7   -2612.8

Measured genotype analysis
--------------------------

We performed measured genotype (MG) tests of association for own genotype (OMG), maternal measured genotype (MMG), and conditional maternal measured genotype (CMMG), for 476,987 autosomal SNPs from the Affymetrix 500k panel. The saturated maternal effects model was used as the null for all analyses. No SNP gave significant evidence of own- or maternal-genotype association with height when corrected for multiple testing using a Bonferroni test (critical test statistic Λ = 28.374 for genome-wide α = 0.05 and 1 df). We did not attempt to account for any linkage disequilibrium among the SNPs in our sample. The SNPs with strongest evidence for OMG, MMG, and CMMG are listed in Table [4](#T4){ref-type="table"}.

###### 

Suggestive associations with height

  SNP^a^                  Gene        Chrom.   Coordinate (bp)   Λ^b^, OMG   Λ^b^, MMG   Λ^b^, CMMG   MAF^c^   N, typed^d^
  ----------------------- ----------- -------- ----------------- ----------- ----------- ------------ -------- -------------
  [Sorted by OMG]{.ul}                                                                                         
  rs2213883               *MPZL1*     1        138,961,675       23.8587     0.8336      0.6778       0.201    6836
  rs12129308              *MCOLN2*    1        83,533,561        20.9235     10.6998     3.0661       0.324    6827
  rs536609                *MCOLN2*    1        83,540,695        20.8421     11.3493     3.4800       0.325    6786
  rs597630                *MCOLN2*    1        83,529,929        20.7087     10.5223     2.9965       0.325    6852
  rs600924                *MCOLN2*    1        83,536,001        20.6884     10.5223     3.0128       0.325    6850
  [Sorted by MMG]{.ul}                                                                                         
  rs11166947              *TRAPPC9*   8        136,376,532       2.3202      24.9813     22.8014      0.322    6271
  rs1426022                           18       16,635,128        3.7962      22.6984     18.9815      0.468    6675
  rs12709669                          18       16,653,893        3.3445      22.6099     19.2853      0.467    6838
  rs756228                *TRAPPC9*   8        141,138,313       2.5298      21.1932     18.6637      0.31     6841
  rs7096364                           10       107,344,433       1.8847      21.1904     19.3774      0.112    6849
  [Sorted by CMMG]{.ul}                                                                                        
  rs11166947              *TRAPPC9*   8        136,376,532       2.3202      24.9813     22.8014      0.322    6271
  rs7607015                           2        81,548,367        0.3632      21.1517     22.1813      0.077    6670
  rs17198973                          4        178,164,796       0.3836      16.228      20.2233      0.401    6848
  rs11048399              *RASSF8*    12       25,992,998        0.9614      20.2601     19.5277      0.042    6787
  rs1195768                           10       107,348,297       1.6268      20.201      18.6879      0.118    6553

^a^Likelihood ratio test statistic (Λ = 2 times the difference in log likelihood of test model and its null)

^b^All MG tests have 1 df

^c^MAF = minor allele frequency.

^d^N, typed = number of genotyped individuals (before imputation).

Discussion
==========

Several recent studies have undertaken genome-wide association analysis of human height \[[@B20]-[@B22]\]. These studies have typically examined very large numbers of individuals (\~10,000-25,000, with multi-stage designs), larger than the 6,775 individuals in the FHS cohort available for this study. These studies agree in finding numerous loci associated with height, as may be expected for a trait long assumed to be polygenic. Under these circumstances, it is not surprising that we did not replicate specific SNPs or locations identified in these larger studies. It should be noted, however, that we did find suggestive evidence of association (OMG) with a broad genomic region identified by Gudbjartsson et al. \[[@B21]\]: 1q24-25 (Table [4](#T4){ref-type="table"}). Our candidate genes in this region is *MPZL1*(OMIM \#604376), a protein tyrosine phosphatase involved in cell proliferation and differentiation. Our next four highest \'hits\' were in the mucolipin2 gene *MCOLN2*on 1p22.

Because the published genome-wide association study on height used unrelated individuals, none reported maternal effects. Interestingly, among our strongest maternal associations are repeated hits in two regions: the *TRAPPC9*gene on chromosome 8 and an intergenic region on chromosome 18. The trafficking protein particle complex 9 gene *TRAPPC9*(*NIBP*) plays a role in neuronal NF-κB signalling \[[@B23]\] but has not, to our knowledge, been associated with stature in any published study. The existence of repeated (albeit suggestive) associations in this gene makes it a candidate for further investigation of the effects of maternal genotype on height.

Conclusion
==========

We have implemented combined random-effects, measured-genotype fixed effects approach for discovery of genetic variants contributing to the indirect effect of maternal genotype on offspring phenotype. We have identified two regions on chromosomes 2 and 8 - with suggestive association at two SNPs in each region - that may contribute to maternal effects on human height. The tools developed here should be of use for a variety of phenotypes and diseases for which an effect of maternal environment is known or suspected, including height, hypertension, birthweight, and the metabolic syndrome.
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